Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.56 |
| ▸ | CTSS | P25774 | 13/20 | 0.56 |
| ▸ | CTSL | P07711 | 4/20 | 0.54 |
| ▸ | CTSB | P07858 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL86185 | 1.00 | CTSK (0.56) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL4118840 | 1.00 | CTSK (0.56) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL28198520 | 0.84 | CTSK (0.52) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL6326266 | 0.84 | CA1 (0.50) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL18055375 | 0.83 | CA1 (0.63) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL14738065 | 0.83 | CTSS (0.54) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL21085559 | 0.83 | CA1 (0.63) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL30993172 | 0.82 | CA1 (0.49) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL30993196 | 0.82 | CA1 (0.49) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL6381798 | 0.81 | CTSK (0.52) | CTSKCTSSCTSLCTSBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638421-A1 | PROCESS TO MAKE GLP1 RA AND INTERMEDIATES THEREFOR | Eli Lilly and Company (US) | 2025-10-29 | — | — | EP | disclosed |
| CN-119874775-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119841865-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-119823184-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119432794-A | Process for preparing (S) -3-aminobutyric acid by transaminase catalysis | 宁波酶赛生物工程有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119431184-A | Synthesis method of (S) -3-aminobutyric acid | 宁波酶赛生物工程有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-115698003-B | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2024-10-11 | — | — | CN | disclosed |
| US-20240279238-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2024-08-22 | — | — | US | disclosed |
| CN-118420491-A | Synthesis process of (S) -3-amino butyronitrile hydrochloride | 镇江中智化学科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-1740547-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1708703-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-10-11 | — | — | EP | disclosed |
| US-20060106061-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2006-05-18 | — | — | US | disclosed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005100321-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-1556047-A2 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2005059107-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2005-06-30 | — | — | WO | disclosed |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004032848-A2 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | GLP1R, GIPR, SLC5A1 | CTSK 2850/4885CTSS 2971/4885CTSL 2994/4885 |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | CTSK 2139/4885CTSS 2461/4885CTSL 2210/4885 |
| US-20060106061-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | CTSK 1976/4885CTSS 2070/4885CTSL 1875/4885 |
| US-20240279238-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | TYMP, CDKN1A, POLL | CTSK 1840/4885CTSS 1337/4885CTSL 1243/4885 |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, PTGDR, LTB4R2 | CTSK 1963/4885CTSS 2123/4885CTSL 1785/4885 |
| US-20050277670-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | CTSK 1957/4885CTSS 1961/4885CTSL 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.